Table 1. Characteristics of the included studies.
| First author | Year | Study design | Ethnicity | Included patients | No. of patients | BIM deletion (%) | Age (years) | Gender (male/female) | Smoking status (smoker/non-smoker) | Adenocarcinoma (%) | EGFR mutation (Exon 19 deletion/L858R/others) | Clinical stage | PFS (median) | OS (median) | Covariants | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ng | 2012 | Retrospective | Asian | NSCLC harboring EGFR-activating mutations | 141 | 18.4 | Wild Type: 59.0 ± 10.4 BIM deletion: 59.7 ± 9.8 |
Wild Type: 40/75 BIM deletion: 7/19 |
Wild Type: 20/94 BIM deletion: 5/20 |
Wild Type: 90.4 BIM deletion: 92.3 |
Wild Type: 65/37/13 BIM deletion: 11/12/3 |
III/IV/Recurrent | Wild Type: 11.9 months BIM deletion: 6.6 months HR = 2.08, 95% CI 1.29–3.38 |
NA | Age, gender, histology, smoking history, type of EGFR mutation by exon and specific mutation, stage, first- or second-line TKI therapy, race, country, TKI (gefitinib or erlotinib) and ECOG status | 9 |
| Lee JK | 2013 | Retrospective | Asian | NSCLC harboring EGFR-activating mutations | 197 | 10.9 | 62 (Range: 31–85) | 73/124 | 52/142 | 97 | 115/72/10 | III/IV/Recurrent | Wild Type: 11.3 months BIM deletion: 11.9 months |
NA | NA | 9 |
| Isobe | 2014 | Retrospective | Asian | NSCLC harboring EGFR-activating mutations | 70 | 18.6 | Wild Type: 65.4 ± 14.1 BIM deletion: 63.8 ± 6.7 |
Wild Type: 15/42 BIM deletion: 4/9 |
Wild Type: 16/41 BIM deletion: 4/9 |
Wild Type: 87.7 BIM deletion: 100 |
Wild Type: 27/28/2 BIM deletion: 6/7/0 |
IV/Recurrent | Wild Type: 17.8 months BIM deletion: 7.57 months HR = 3.99, 95% CI 1.86–8.55 |
Wild Type: 45.4 months BIM deletion: 39.2 months |
Age, sex, performance status, brain metastasis, bone metastasis, pulmonary metastasis, liver metastasis, lymph node metastasis, EGFR mutation, EGFR-TKI response, smoking history | 9 |
| Zhao | 2014 | Retrospective | Asian | Advanced NSCLC harboring EGFR-activating mutations | 352 | 12.8 | Wild Type: 59 (Range: 32–81) BIM deletion: 59 (Range: 39–75) |
Wild Type: 153/154 BIM deletion: 20/25 |
Wild Type: 82/225 BIM deletion: 15/30 |
Wild Type: 78.2 BIM deletion: 73.3 |
Wild Type: 107/90/3 BIM deletion: 15/12/1 |
IIIb/IV | Wild Type: 11 months BIM deletion: 4.7 months HR = 2.09, 95% CI 1.15–3.82 |
NA | Age, sex, smoke, EGFR mutational status | 9 |
| Zhong | 2014 | Retrospective | Asian | NSCLC harboring EGFR-activating mutations | 191 | 15.5 | Wild Type: 58.3 ± 11.7 BIM deletion: 60.0 ± 11.0 |
Wild Type: 105/140 BIM deletion: 23/22 |
Wild Type: 82/163 BIM deletion: 20/25 |
Wild Type: 82.9 BIM deletion: 77.8 |
Wild Type: 90/60/11 BIM deletion: 10/17/3 |
I to IV | Wild Type: 8.47 months BIM deletion: 6.69 months |
Wild Type: 21.9 months BIM deletion: 21.9 months |
Age, gender, smoking history, tumor stage, differentiation | 8 |
NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; BIM, Bcl-2-like protein 11; PFS, progression-free survival; OS, overall survival; TKI, tyrosine kinase inhibitor; NA, not available.